Lv51
1530 积分 2024-06-14 加入
Abstract PD3-14: Phase 1 study of the antibody-drug conjugate SGN-LIV1A in patients with heavily pretreated triple-negative metastatic breast cancer
15天前
已关闭
HER2 testing: evolution and update for a companion diagnostic assay
21天前
已完结
CD47 Contributes to the Proliferation of Breast Cancer
23天前
已关闭
A Phase II Trial of Onapristone and Fulvestrant for Patients with ER+ and HER2- Metastatic Breast Cancer
28天前
已关闭
Association between the Chinese Dietary Balance Index-based dietary quality and depressive symptoms in breast cancer patients
1个月前
已完结
Neoadjuvant therapy in HER2-positive breast cancer and interim PET
1个月前
已关闭
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
1个月前
已完结
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial
1个月前
已完结
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
1个月前
已完结
MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study
1个月前
已完结
皖公网安备34019202002308
